GlobalData on MSN4mon
Palvella secures FDA grant for Phase III microcystic LMs treatment trialPalvella initiated the SELVA trial of QTORIN rapamycin for microcystic LMs in the third quarter of 2024. This 24-week, single ...
SELVA study principal investigator and Stanford University Dermatology and Pediatrics professor Joyce Teng said: “Patients with microcystic LMs often have lymphorrhoea, bleeding, infection ...
Palvella's expansion of the SELVA clinical trial to include patients aged 3 to 5 years old demonstrates a commitment to addressing the needs of younger patients suffering from microcystic LMs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback